非布司他和别嘌呤醇治疗KDIGO分级4~5期慢性肾病伴高尿酸血症的临床效果比较

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (552 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate clinical effect of Febuxostat and Allopurinol in the treatment of KDIGO grade four to five chronic nephropathy (CKD) with hyperuricemia (HUA). Methods One hundred and thirty-four patients with CKD and HUA of KDIGO grade four to five admitted to the First People’s Hospital of Lianyungang City from August 2016 to January 2019 were selected and divided into allopurinol group and febuxostat group according to random number table method, with 67 cases in each group. The course of treatment was six months. The standard rate of serum uric acid (SUA) in the first to six months of treatment, adverse reaction, body mass index, systolic blood pressure, total cholesterol (TC), triglyceride, low density lipoprotein-cholesterol (LDL-C), SUA, blood urea nitrogen (BUN), serum creatinine (Scr), estimate glomerular filtration rate (eGFR) and 24 h urinary protein before and after treatment were compared between two groups. Results The standard rate of SUA in febuxostat group was higher than that in allopurinol group at one, two, three, four, five and six months after treatment, the differences were statistically significant (P < 0.05). Six months after treatment, the incidence rate of adverse reaction in febuxostat group was lower than that in allopurinol group, the difference was statistically significant (P < 0.05). After treatment, TC, LDL-C, SUA, BUN, Scr and 24 hours urinary protein in febuxostat group were lower than those before treatment and allopurinol group, and eGFR in febuxostat group was higher than that before treatment and allopurinol group, the differences were statistically significant (P < 0.05). After treatment, BUN in allopurinol group was significantly lower than that before treatment, the difference was statistically significant (P < 0.05). Conclusion Febuxostat can reduce the SUA level of CKD and HUA patients with grade four to five of KDIGO, reduce Scr and proteinuria, and improve renal function.

Key words： KDIGO classification Chronic kidney disease Hyperuricemia Febuxostat Allopurinol

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yiwen1 ZHANG Liyuan1▲ GUO Yibin2

Cite this article:

ZHANG Yiwen1 ZHANG Liyuan1▲ GUO Yibin2. Comparison of clinical effect of Febuxostat and Allopurinol in the treatment of KDIGO grade four to five chronic nephropathy with hyperuricemia[J]. 中国医药导报, 2021, 18(3): 62-66.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I3/62

[1] 孙琳，王桂侠，郭蔚莹.高尿酸血症研究进展[J].中国老年学杂志，2017，37（4）：1034-1038.
[2] 陈光亮，周媛凤，张颖，等.治疗痛风和高尿酸血症药物研究进展[J].中国临床药理学与治疗学，2017，22（1）：104-109.
[3] 侯金花，蒋琦，刘志红.2017 KDIGO临床实践指南更新：慢性肾脏病矿物质与骨异常诊断、评估、预防和治疗[J].肾脏病与透析肾移植杂志，2017，26（5）：462-466.
[4] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组，高翔，梅长林.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志，2017，37（1）：33-39.
[5] 王惠芳，张伟，李宁，等.非布司他治疗慢性肾脏病3-5期伴高尿酸血症患者的疗效分析及对肾功能的影响[J].中华肾脏病杂志，2017，33（10）：721-728.
[6] 朱和同，李先维.非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效与安全性[J].中国医院用药评价与分析，2017，17（7）：892-894.
[7] 心血管疾病合并高尿酸血症诊治专家共识专家组.无症状高尿酸血症合并心血管疾病诊治建议中国专家共识[J].中国当代医药，2009，2（24）：49-55.
[8] Pottel H，Hoste L，Dubourg L，et al. An estimated glomerular filtration rate equation for the full age spectrum [J]. Nephrol Dial Transplant，2016，31（5）：798-806.
[9] 邢慧媛，刘琰，赵艾，等.吸烟、饮酒和膳食因素对高尿酸血症人群中高血压的影响[J].中华疾病控制杂志，2018， 22（6）：555-559.
[10] 黄叶飞，欧嘉勇，刘琪，等.不同运动频次对高尿酸血症患者痛风发作影响的研究[J].新医学，2018，9（5）：355-358.
[11] Kim S，Kim HJ，Ahn HS，et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia：a systematic review and meta-analysis [J]. Kidney Res Clin Pract，2017，36（3）：274-281.
[12] 董非斐，吉晓理，符薇薇，等.非布司他治疗高尿酸血症效果及安全性[J].青岛大学医学院学报，2019，55（4）：492-495，498.
[13] 龚书豪，卢婉君，欧阳柳荣，等.非布司他治疗慢性肾脏病伴高尿酸血症患者疗效及对肾功能影响的Meta分析[J].天津医药，2018，46（10）：1102-1107.
[14] 赵洪静，杨沿浪，叶寅寅，等.非布司他治疗高尿酸血症的研究进展[J].安徽医学，2018，39（2）：239-241.
[15] 李治成，唐志刚，郑巧，等.非布司他联合前列地尔治疗慢性肾衰竭的疗效及高尿酸血症对血液流变学的影响[J].河北医学，2019，25（8）：1336-1339.
[16] Yu H，Liu X，Song Y，et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease：a prospective pilot study [J]. Clin Exp Nephrol，2018，22（4）：1-7.
[17] 咸伟，董吉，周朝阳，等.非布司他治疗慢性肾病伴高尿酸血症的疗效和机制分析[J].药物评价研究，2019，42（3）：517-520.
[18] 陈松，黄健，杨静，等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志，2016，32（3）：472-474.
[19] 苗艳，吴俊，闫磊，等.非布司他治疗非终末期糖尿病肾病合并高尿酸血症的有效性及其对肾功能的影响[J].中国全科医学，2019，22（10）：1192-1197.
[20] 姜佳佳，张武军，王长希，等.非布司他治疗肾移植后高尿酸血症的有效性和安全性[J].中华器官移植杂志，2019， 40（3）：158-161.
[21] 宋柳全，谭焕原，谢宝超，等.非布司他在慢性肾脏病合并高尿酸血症治疗中的应用价值分析[J].山东医药，2019， 59（14）：60-62.
[22] 章敏巧，张荣国.非布司他治疗慢性肾脏病3-5期合并高尿酸血症有效性和安全性观察[J].浙江中西医结合杂志，2017，27（5）：394-395.
[23] Ito H，Antoku S，Abe M，et al. Comparison of the renoprotective effect of febuxostat for the treatment of hyperuricemia between patients with and without type 2 diabetes mellitus：a retrospective observational study [J]. Intern Med，2016，55（22）：3247-3256.
[24] 蔡鸿福，王丽莉，陈深，等.非布司他治疗高尿酸血症有效性及安全性的Meta分析[J].循证医学，2019，19（2）：102-108.
[25] 任广伟，李明明，杨洪娟，等.非布司他对维持性血液透析伴高尿酸血症患者血清炎性因子水平和肝功能的影响[J].河北医药，2018，40（14）：92-95，99.
[26] 吴玮芳，陈宝军，金莉娜.非布司他对高尿酸血症痛风患者血清炎症因子及血管内皮细胞的影响及疗效观察[J].中国现代医生，2020，58（10）：122-125.
[27] Meenu P，Kumar YA，Luhadia SK，et al. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients [J]. Indian J Pharmacol，2016，48（5）：522-525.